The expression of osteoclastogenesis‐associated factors and osteoblast response to osteolytic prostate cancer cells
- 28 October 2009
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 70 (4), 412-424
- https://doi.org/10.1002/pros.21075
Abstract
BACKGROUND Prostate cancer (PCa) has a propensity to metastasize to bone. Tumor cells replace bone marrow and can elicit an osteoblastic, osteolytic, or mixed bone response. Our objective was to elucidate the mechanisms and key factors involved in promoting osteoclastogenesis in PCa bone metastasis. METHODS We cultured osteoblast‐like MC3T3‐E1 cells with conditioned medium (CM) from PC‐3 and C4‐2B cells. MC3T3‐E1 mineralization decreased in the presence of PC‐3 CM, whereas C4‐2B CM had no effect on mineralization. Using oligo arrays and validating by real‐time PCR, we observed a decrease in the expression of mineralization‐associated genes in MC3T3‐E1 cells grown in the presence of PC‐3 CM. In addition, PC‐3 CM induced the expression of osteoclastogenesis‐associated genes IGFBP‐5, IL‐6, MCP‐1, and RANKL while decreasing OPG expression in MC3T3‐E1 cells. Furthermore, CM from MC3T3‐E1 cells cultured in the presence of PC‐3 CM, in association with soluble RANKL, increased osteoclastogenesis in RAW 264.7 cells. Investigation of PCa metastases and xenografts by immunohistochemistry revealed that the osteoclastic factor IL‐6 was expressed in the majority of PCa bone metastases and to a lesser extent in PCa soft tissue metastases. In vitro it was determined that soluble IL‐6R (sIL‐6R) was necessary for IL‐6 to inhibit mineralization in MC3T3‐E1 cells. RESULTS PC‐3 cells inhibit osteoblast activity and induce osteoblasts to produce osteoclastic factors that promote osteoclastogenesis, and one of these factors, IL‐6, is highly expressed in PCa bone metastases. CONCLUSIONS IL‐6 may have an important role in promoting osteoclastogenesis in PCa bone metastasis through its' interaction with sIL‐6R. Prostate 70: 412–424, 2010.Keywords
Funding Information
- Office of Research and Development Medical Research Service
- Department of Veterans Affairs
- Department of Defense Consortium (DAMD170320033)
- PO1 National Institutes of Health grant (PO1CA085859)
- Pacific Northwest Prostate Cancer SPORE (P50CA097186)
- Richard M. LUCAS Foundation
- Prostate Cancer Foundation
This publication has 27 references indexed in Scilit:
- Histopathological Assessment of Prostate Cancer Bone Osteoblastic MetastasesJournal of Urology, 2008
- Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastasesClinical & Experimental Metastasis, 2007
- Endogenous Bone Morphogenetic Protein-7 Controls the Motility of Prostate Cancer Cells Through Regulation of Bone Morphogenetic Protein AntagonistsJournal of Urology, 2007
- Monocyte Chemotactic Protein-1 Mediates Prostate Cancer–Induced Bone ResorptionCancer Research, 2007
- Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSFMolecular Cancer, 2007
- Characterization of C4–2 Prostate Cancer Bone Metastases and Their Response to CastrationJournal of Bone and Mineral Research, 2003
- Shedding of the Interleukin-6 (IL-6) Receptor (gp80) Determines the Ability of IL-6 to Induce gp130 Phosphorylation in Human OsteoblastsOnline Journal of Public Health Informatics, 2002
- Expression of monocyte chemoattractant protein 1 in human osteoblastic cells stimulated by proinflammatory mediatorsJournal of Bone and Mineral Research, 1994
- Molecular cloning and expression of an IL-6 signal transducer, gp130Cell, 1990
- Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesisBiochemical and Biophysical Research Communications, 1989